Added to YB: 2025-12-03
Pitch date: 2025-11-30
NVO [neutral]
Novo Nordisk A/S
-22.25%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 304.68
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
turnaround
Can They Work Again? - Novo Nordisk A/S
NVO (update): GLP-1 obesity/diabetes market projected >$100B globally next decade. Down on US price negotiations & failed Alzheimer's study, but lower prices = broader gov't patient access potentially offsetting unit price decline. International growth matching US. Author holds 70% 5yr gains, monitoring for consolidation.
Read full article (2 min)